Found: 5
ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ2018
Temirbulatov I.I., Ivashchenko D.V., Rudykh Z.A., Popova N.V., Tayurskaya K.S., Chertovskikh Ya.V., Sychev D.A.
Introduction. Proton pump inhibitors (PPI) are widely spread as antisecretory drugs for a treatment of acid diseases, such as the gastric ulcer. Most of the proton pump inhibitors are inactivated in the liver by cytochromes P450 2C19 (CYP2C19) to the form of i…
ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ2018
Mirzaev K.B., Fedorinov D.S., Sychev D.A., Maksimova N.R., Chertovskih Ya.V., Popova Ya.V., Tayurskaya K.S., Rudykh Z.A.
ntroduction. The aim of this study was to determine the prevalence rate of CYP2C19 alleles, associated with the risk of the resistance to clopidogrel and the development of thrombotic complications in patients with acute coronary syndrome (ACS) from Russian an…
ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ2017
Kochergina A.M., Kashtalap V.V., Gordeeva L.A., Kochergin N.A., Barbarash O.L.
Aim is to evaluate distribution and clinical significance of gene CYP2C19 polymorfism in ST-segment elevation myocardial infarction (STEMI) patients. Materials and methods. A total of 159 patients were encluded in this study. All of them underwent primary PCI.…
ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ2015
Denisenko N.P., Sychev D.A., Sizova Zh.M., Kazakov R.E., Grachev A.V.
Introduction. Cytochrome P-450 2C19 is the main isoenzyme responsible for the metabolism of proton pump inhibitors, the main group of drugs for treating stomach and duodenal ulcer. There are genetic differences that affect the activity of this enzyme: there ar…
Research article2014
Mirzaev K.B., Sychev D.A., Andreev D.A.
Genetically determined diversity in the activity of enzymes regulating the biotransformation of drugs and xenobiotics - cytochrome P450 (CYP) is one of the main causes of interindividual differences in the response of pharmacotherapy. The objective of this rev…